KYMR vs. PCVX: Kymera Therapeutics vs. Vaxcyte Stock Comparison

November 11, 2026

How do Kymera Therapeutics (KYMR) and Vaxcyte (PCVX) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Kymera Therapeutics (KYMR) and Vaxcyte (PCVX) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Company profile comparison for Kymera Therapeutics (KYMR) and Vaxcyte (PCVX)
Profile Item	KYMR	PCVX
Name	Kymera Therapeutics Inc.	Vaxcyte Inc.
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Biotechnology
GICS Sub-Industry	Biotechnology	Biotechnology
Market Capitalization	11.25 billion USD	10.11 billion USD
Currency	USD	USD
Exchange	Nasdaq	Nasdaq
Listing Date	August 21, 2020	June 12, 2020
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

KYMR

PCVX

GSPC

Kymera Therapeutics (KYMR) vs. Vaxcyte (PCVX), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Kymera Therapeutics (KYMR) and Vaxcyte (PCVX). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Kymera Therapeutics (KYMR) and Vaxcyte (PCVX). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Kymera Therapeutics (KYMR) and Vaxcyte (PCVX)
Metric	KYMR	PCVX
Total Return (1Y)	131.52%	59.00%
Total Return (3Y, Annualized)	111.65%	11.29%
Total Return (5Y, Annualized)	15.68%	21.60%

Risk Profile

Drawdown History

KYMR

PCVX

GSPC

Kymera Therapeutics (KYMR) vs. Vaxcyte (PCVX), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Kymera Therapeutics (KYMR) and Vaxcyte (PCVX). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Kymera Therapeutics (KYMR) and Vaxcyte (PCVX)
Metric	KYMR	PCVX
Volatility (1Y, Annualized)	62.83%	56.01%
Beta (5Y)	2.00	1.26
Max Drawdown (5Y)	-83.27%	-76.22%
Avg. Volume (3M)	833.05K	2.12M

Risk-Adjusted Performance

Risk-Return Positioning

KYMR and PCVX are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Kymera Therapeutics (KYMR) and Vaxcyte (PCVX)
Metric	KYMR	PCVX
Sharpe Ratio (1Y)	2.03	0.98
Sortino Ratio (1Y)	4.16	1.76

Profitability

ROE (TTM)

Both Kymera Therapeutics (KYMR) at -27.29% and Vaxcyte (PCVX) at -42.68% report negative ROE values. Negative ROE can reflect losses or negative shareholders’ equity, so both readings need extra context.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

-27.29%

Max: 109.18%
Q3: 6.23%
Median: -26.66%
KYMR: -27.29%
Q1: -64.05%
Min: -167.77%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

-42.68%

Max: 109.18%
Q3: 6.23%
Median: -26.66%
PCVX: -42.68%
Q1: -64.05%
Min: -167.77%

Kymera Therapeutics (KYMR) vs. Vaxcyte (PCVX): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Both Kymera Therapeutics (KYMR) at 0.00% and Vaxcyte (PCVX) at 0.00% keep about the typical share of revenue as profit for their industries — neither bottom line stands out from peers.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max: 18.05%
Q3: 4.78%
KYMR: 0.00%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max: 18.05%
Q3: 4.78%
PCVX: 0.00%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Kymera Therapeutics (KYMR) vs. Vaxcyte (PCVX): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Kymera Therapeutics (KYMR) reports a negative operating margin of -396.04%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Vaxcyte (PCVX) reports 0.00%, ranking against industry peers normally.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

-396.04%

Max: 83.12%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%
KYMR: -396.04%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max: 83.12%
Q3: 14.77%
PCVX: 0.00%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Kymera Therapeutics (KYMR) vs. Vaxcyte (PCVX): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Kymera Therapeutics (KYMR) and Vaxcyte (PCVX)
Metric	KYMR	PCVX
ROE (TTM)	-27.29%	-42.68%
ROA (TTM)	-17.64%	-24.98%
Net Margin (TTM)	0.00%	0.00%
Operating Margin (TTM)	-396.04%	0.00%
Gross Margin (TTM)	0.00%	0.00%

Growth

Revenue Growth

Only one side can be read here: Kymera Therapeutics (KYMR) reports revenue growth of -16.70%, ranked against its industry; Vaxcyte (PCVX) has no revenue growth figure this period.

Kymera Therapeutics (KYMR) vs. Vaxcyte (PCVX): A comparison of their Revenue Growth across different time periods.

EPS Growth

Neither Kymera Therapeutics (KYMR) nor Vaxcyte (PCVX) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Growth metrics for Kymera Therapeutics (KYMR) and Vaxcyte (PCVX)
Metric	KYMR	PCVX
Revenue Growth (YoY)	-16.70%	--
Revenue Growth (3Y CAGR)	-5.74%	--
EPS Growth (YoY)	--	--
EPS Growth (3Y CAGR)	--	--

Financial Strength

Current Ratio (MRQ)

Both Kymera Therapeutics (KYMR) at 11.13 and Vaxcyte (PCVX) at 4.56 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

11.13

Max: 25.13
Q3: 12.13
KYMR: 11.13
Median: 5.52
Q1: 2.47
Min: 0.10

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.56

Max: 25.13
Q3: 12.13
Median: 5.52
PCVX: 4.56
Q1: 2.47
Min: 0.10

Kymera Therapeutics (KYMR) vs. Vaxcyte (PCVX): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Kymera Therapeutics (KYMR) at 0.05 and Vaxcyte (PCVX) at 0.09 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.05

Max: 1.42
Q3: 0.65
Median: 0.15
KYMR: 0.05
Q1: 0.02
Min: 0.00

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.09

Max: 1.42
Q3: 0.65
Median: 0.15
PCVX: 0.09
Q1: 0.02
Min: 0.00

Kymera Therapeutics (KYMR) vs. Vaxcyte (PCVX): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Kymera Therapeutics (KYMR) and Vaxcyte (PCVX)
Metric	KYMR	PCVX
Current Ratio (MRQ)	11.13	4.56
Debt / Equity (MRQ)	0.05	0.09
Net Debt / EBITDA	--	--

Dividends

Dividend Yield (TTM)

Neither Kymera Therapeutics (KYMR) nor Vaxcyte (PCVX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

KYMR: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

PCVX: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Kymera Therapeutics (KYMR) vs. Vaxcyte (PCVX): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Kymera Therapeutics (KYMR) nor Vaxcyte (PCVX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

KYMR: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

PCVX: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Kymera Therapeutics (KYMR) vs. Vaxcyte (PCVX): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Kymera Therapeutics (KYMR) and Vaxcyte (PCVX)
Metric	KYMR	PCVX
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

P/E Ratio (TTM)

Neither Kymera Therapeutics (KYMR) nor Vaxcyte (PCVX) reports a P/E ratio value for this period, so a direct comparison isn’t possible.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07
KYMR: --

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07
PCVX: --

Kymera Therapeutics (KYMR) vs. Vaxcyte (PCVX): Neither stock reports P/E ratio, so the chart shows available benchmark boxes without value markers.

P/S Ratio (TTM)

A sales-based read is only available for Kymera Therapeutics (KYMR), whose P/S ratio of 110.00 ranks against industry peers; Vaxcyte (PCVX) reports no figure this period.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

110.00

KYMR: 110.00
Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
Min: 0.01

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
Min: 0.01
PCVX: --

Kymera Therapeutics (KYMR) vs. Vaxcyte (PCVX): PCVX does not report P/S ratio, so it has no value marker; KYMR is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/B Ratio (MRQ)

Vaxcyte (PCVX) at 3.83 is valued about in line with its industry on P/B ratio, while Kymera Therapeutics (KYMR) at 6.96 carries an above-peer premium to book — KYMR is pricier on assets.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.96

Max: 13.53
KYMR: 6.96
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.83

Max: 13.53
Q3: 6.54
PCVX: 3.83
Median: 3.25
Q1: 1.69
Min: -5.59

Kymera Therapeutics (KYMR) vs. Vaxcyte (PCVX): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Kymera Therapeutics (KYMR) and Vaxcyte (PCVX)
Metric	KYMR	PCVX
P/E Ratio (TTM)	--	--
P/S Ratio (TTM)	110.00	--
P/B Ratio (MRQ)	6.96	3.83
Free Cash Flow Yield (TTM)	-1.46%	-5.24%